A 52-Week, Open-Label Study Evaluating the Safety and Efficacy of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, for Rheumatoid Arthritis

Arthritis Research and Therapy - United Kingdom
doi 10.1186/s13075-014-0415-2
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Efficacy and Safety of Subcutaneous Tabalumab, a Monoclonal Antibody to B-Cell Activating Factor, in Patients With Systemic Lupus Erythematosus: Results From ILLUMINATE-2, a 52-Week, Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2015English

Long-Term Efficacy and Safety of RPC4046, an Anti-Interleukin-13 Monoclonal Antibody, in Patients With Eosinophilic Esophagitis: Results From the Open-Label Extension of the HEROES Study

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

A Multicentre Open-Label Safety and Efficacy Study of Tetrodotoxin for Cancer Pain

Current Oncology
Oncology
2011English

SAT0236 Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral Jak-1 Inhibitor in Patients With Rheumatoid Arthritis in an Open Label Extension Study

2018English

Anti-CCP Antibody and Rheumatoid Factor Positivity in a Case of Tuberculosis Arthritis

Turkish Journal of Rheumatology
2010English

Safety and Efficacy of Tofacitinib for Up to 9.5 Years in the Treatment of Rheumatoid Arthritis: Final Results of a Global, Open-Label, Long-Term Extension Study

Arthritis Research & Therapy
2019English

Safety and Efficacy From an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents With Schizophrenia

Journal of Child and Adolescent Psychopharmacology
Mental HealthChild HealthPharmacologyPerinatologyPsychiatryPediatrics
2015English

Efficacy and Safety of an Intravenous Monoclonal Anti-HBs in Chronic Hepatitis B Patients

Liver International
Hepatology
2001English

B Cell Therapy for Rheumatoid Arthritis: The Rituximab (Anti-Cd20) Experience

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2003English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy